Skip to main content

Genomics-Based Cancer Care

Delivering genomics-based cancer care for every community



Genomics has the power to transform cancer care, but only if it is implemented equitably and inclusively.

Australia has the world’s best cancer outcomes, but certain populations — including Aboriginal and Torres Strait Islander people, those living in rural and remote areas, culturally and linguistically diverse groups, and people with rare cancers — do not share this experience and have limited access to cutting-edge technologies. Addressing these disparities requires a multifaceted approach.

Recognising the critical importance of genomics in cancer care, the Australian Government launched the National Framework for Genomics in Cancer Control in February 2025 as a key action of the Australian Cancer Plan. The vision of this framework is clear: to integrate cancer genomics into routine clinical practice as the standard of care while ensuring accessibility, cultural safety and equity across the cancer care continuum. Together with the upcoming launch of Genomics Australia, we have a significant opportunity to align efforts and accelerate the integration of genomics in cancer care.

Last month, the Australian Government announced the establishment of a $3 million Cancer Genomics Clinical Trials Fund to drive advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics. This new fund is a significant first step in implementing the framework and addressing key objectives for genomics-informed diagnosis, treatment, clinical trials, research and data.

The role of genomics in cancer care


Cancer is fundamentally a disease of the genome, involving mutations in DNA that can lead to uncontrolled cell growth. With advances in technology, we can identify genetic predispositions to cancer, enabling early intervention and personalised risk-reduction strategies. Genomic testing can also help determine the most effective, least toxic treatment plans, improving patient outcomes and quality of life.

The need for genomic literacy in cancer care


While the rapid advancement of genomics offers exciting possibilities, it also presents challenges, including the need for improved genomics literacy among both health care professionals and the broader public.

The volume of available information on genomics is expanding rapidly. It is crucial that patients can access accurate, reliable and evidence-based information and that medical professionals remain a trusted source for genomics guidance. This includes an understanding of the germline and somatic testing, the role of cascade testing, and the types of genomic testing, including whole genome sequencing, panel testing and tumour mutational burden.

To support clinicians in navigating these complexities, resources such as the eviQ referral guidelines for cancer genetics assessment are essential. By equipping health professionals with practical tools, we can improve personalised prevention, risk-reducing strategies, early detection and personalised treatment plans, ultimately leading to better patient outcomes.

Addressing equity: ensuring genomics benefits all Australians


Equity in cancer care is a fundamental measure of success under the framework. Without intentional efforts to improve access, there is a risk that genomic advancements will exacerbate existing health care inequities.

Ensuring culturally safe genomics-guided cancer care is a priority. This requires ongoing consultation and collaboration with Aboriginal and Torres Strait Islander communities who have higher cancer mortality rates and face barriers in accessing genomics-informed care.

In 2024, Cancer Australia conducted in-person workshops with Aboriginal and Torres Strait Islander community members, cancer patients, health care providers and community-controlled health services. These consultations reinforced the importance of self-determination, culture, capacity building, and access in shaping the future of cancer genomics care.

Moving forward: what needs to happen next?


The launch of the framework is just the beginning. Successful implementation requires a coordinated effort from the entire health care sector, including governments, researchers, health care providers, and advocacy groups.

Cancer Australia has identified four key priorities for implementation:


Integration into routine clinical practice


  • Establishing genomics as a standard component of cancer care to enable personalised cancer prevention and early detection and to guide treatment decisions.
  • Ensuring evidence-based genomic testing is available and accessible to patients regardless of geographic location or socio-economic status.
  • Promoting translational research and enabling timely access to genomics-informed cancer treatments through Health Technology Assessment processes and clinical trials.

Public awareness and workforce education and training


  • Enhancing genomics literacy among all health care professionals to ensure clinicians are confident in using genomics to guide cancer prevention and treatment.
  • Developing community awareness campaigns about cancer genomics and co-designing resources with priority populations and consumers.
  • Driving system level changes relating to cultural safety, with education for health providers that acknowledges the complex history of genomics for Aboriginal and Torres Strait Islander people.

Data and research

  • Strengthening data-sharing capabilities to maximise the benefits of genomics research and improve real-world applications.
  • Ensuring cancer genomic research and data are representative of population diversity, underpinned by Indigenous data sovereignty principles.

Equity and cultural safety

  • Developing tools for the specialist cancer workforce and primary care, including Aboriginal Community Controlled Health Services, to support shared decision making with patients about the use of genomics in cancer care.
  • Providing Aboriginal and Torres Strait Islander people and other priority populations with holistic navigation support and wrap-around personalised genomic cancer care.

Conclusion


Genomics has the power to transform cancer care, but only if it is implemented equitably and inclusively. The National Framework for Genomics in Cancer Control provides a roadmap for ensuring all Australians, regardless of background or location, can benefit from the latest advancements in personalised cancer care. However, achieving this vision requires commitment from the entire health care sector. Cancer Australia is committed to leading this charge, ensuring that genomics serves as a tool for better outcomes, improved patient experiences, and a more equitable cancer care for all Australians.

Genomics, DNA sequencing, genetic variation, gene expression, epigenetics, CRISPR, genome editing, bioinformatics, personalized medicine, transcriptomics, proteomics, metagenomics, population genetics, evolutionary genetics, functional genomics, structural genomics, synthetic biology, molecular diagnostics, gene therapy, pharmacogenomics,

#Genomics #DNASequencing #GeneticVariation #GeneExpression #Epigenetics #CRISPR #GenomeEditing #Bioinformatics #PersonalizedMedicine #Transcriptomics #Proteomics #Metagenomics #PopulationGenetics #EvolutionaryGenetics #FunctionalGenomics #StructuralGenomics #SyntheticBiology #MolecularDiagnostics #GeneTherapy #Pharmacogenomics

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more